Product Description
TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression.
Mechanisms of Action: MGLUR2/3 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Taisho Pharmaceutical R&D Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Depressive Disorder, Treatment-Resistant|Depressive Disorder, Major
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03919409 |
TS161-US101 | P1 |
Completed |
Healthy Volunteers |
2020-02-11 |
50% |
2020-02-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04821271 |
000101-M | P2 |
Terminated |
Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant |
2024-05-23 |
12% |
2025-06-11 |
Primary Endpoints|Treatments|Trial Status |